A comprehensive observational cohort study has quantified a concerning association between glucosamine supplementation and accelerated cognitive decline. Among adults diagnosed with mild cognitive impairment, those taking glucosamine supplements showed a 25% higher likelihood of progressing to Alzheimer’s disease compared to non-users.
This statistic represents one of the largest investigations into glucosamine’s neurological effects, tracking participants across multiple countries over several years. The unexpected finding contradicts the supplement’s reputation for safety, prompting researchers to examine inflammatory pathways as potential biological mechanisms linking joint supplement use to brain health deterioration.
Given that glucosamine is one of the most consumed over-the-counter supplements globally, these results warrant immediate attention from healthcare providers, patients, and regulatory bodies monitoring supplement safety.
Read the full article on GMJ Newsroom.
Was this article helpful?
